NNVC

Announcements

Nothing here yet

Daily updates

• NanoViricides was set to begin patient dosing in its Phase 2 Ebola trial in the Democratic Republic of CongoSep 17, 2026

FDA designations

Nothing here yet

News

• NanoViricides says enrollment and dosing began last week, around September 23, in the clinical trial of oral NV-387 for EbolaSep 28, 2026
• NanoViricides announces the start of a Phase 2 clinical trial of NV-387 for the treatment of mpox in the Democratic Republic of the CongoSep 23, 2026
• NanoViricides announced that a clinical trial of oral NV-387 for Ebola is expected to begin next week as the outbreak expands in the Democratic Republic of the CongoSep 15, 2026
• The Phase 2 trial of NV-387 oral gummies for Ebola in the Democratic Republic of the Congo is expected to begin soonAug 18, 2026
• NanoViricides received regulatory approval to conduct a Phase 2 trial of NV-387 oral gummies for Ebola treatment in the Democratic Republic of the CongoAug 10, 2026